Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), highlighting significant regulatory progress for the company's lead candidate, OST-HER2, in recurrent, fully resected, pulmonary metastatic osteosarcoma. The key development is greater regulatory clarity: the European Medicines Agency (EMA) has initiated rolling review of the OST-HER2 Conditional Marketing Authorization dossier, while the EMA and Australia's Therapeutic Goods Administration (TGA) have aligned on 3-year overall survival (OS) as the approvable efficacy endpoint. Management has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence, shifting the investment debate from early proof-of-concept toward execution across a dense 2026 catalyst calendar.
The updated analysis emphasizes that regulatory clarity is the core value inflection. The EMA rolling review, TGA endpoint alignment, UK Medicines and Healthcare products Regulatory Agency (MHRA) Advanced Therapy Medicinal Product (ATMP) designation, and planned 2026 FDA/MHRA meetings collectively shift OST-HER2 from Phase 2b validation toward an executable global approval pathway. Stonegate notes that survival data remain the key catalyst stack, with 2.5-year OS data expected in mid-second quarter 2026 and 3-year OS data in early fourth quarter 2026. These data points will determine whether OS Therapies can complete the EMA Conditional Marketing Authorization submission and sustain accelerated-access momentum.
Financing and Priority Review Voucher (PRV) optionality are expected to bridge the regulatory window. The $5.25 million capital raise, combined with expected $4.0 million in non-dilutive funding, supports the 2026 catalyst milestones. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction valued at $205 million. Key near-term catalysts include 2.5-year OS data in mid-2Q26, FDA/MHRA meetings in 2Q26, Phase 3 initiation in Australia in 3Q26, 3-year OS data in early 4Q26, and a potential EMA Conditional Marketing Authorization decision in 4Q26. For more details, the full announcement can be accessed here.